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Abstract
By international standards, Ireland is a relatively small dairy producer. However, the industry plays a critical role to
the national economy, accounting for approximately 3% of national gross domestic product. This paper presents
insights into udder health and intramammary antibiotic usage on Irish dairy farms during 2003-2010, based on data
from several sources. Three data sources were used, including data on milk recording data, intramammary
antibiotic sales and animal health assessment. The milk recording data included a single unadjusted herd-level
somatic cell count (SCC) value for each herd at each milk recording, being the arithmetic mean of cow-level SCC
of each cow at that recording, weighted by cow-level yield. These data were used to calculate the percentage of
herds each month where the unadjusted herd SCC exceeded 200,000 and 400,000 cells/mL. Two logistic
generalised estimating-equations (GEE) models were developed, the outcome variable being either the probability
that the monthly SCC of a herd was greater than 400,000 cells/mL or less than or equal to 200,000 cells/mL. Spring
herds had a lower probability of a high SCC (> 400,000 cells/mL) during February to October compared to non-
Spring herds but a higher probability between November to January. The odds of a high SCC were greater in
2005, 2006, 2009 and 2010 but less in 2007 and 2008 compared to 2004. Smaller herds had higher odds of having
a high SCC compared to larger herds. We present the number of intramammary tubes and the quantity of active
substance (kg) sold annually in Ireland during 2003-2010. We infer an incidence of clinical mastitis of 54.0 cases per
100 cow-years at risk, assuming 4 tubes per treatment regime, one affected quarter per cow, tubes restricted to
clinical cases only and 100% of treated cases considered new cases, based on data collected on sales of in-
lactation intra-mammary antibiotics. With differing assumptions, this estimate varied between 25.8 and 77.0 cases
per 100 cow-years at risk. Using data on sales of dry cow therapy intra-mammary antibiotics, we also infer that
most Irish dairy farmers use blanket dry cow therapy. It is important that Ireland has an objective understanding of
current levels of udder health, to facilitate benchmarking and improvement into the future. Udder health is a
concern on a number of Irish dairy farms. High SCC results were present throughout the year, but more marked
towards the start and end of each milking season. Animal Health Ireland recently commenced a major national
programme, CellCheck, in collaboration with a broad range of stakeholders, to support national SCC improvement.
In this paper, relevant European and national legislation is also reviewed.
Introduction
By international standards, Ireland is a relatively small
dairy producer [1]. During 2003 to 2007, the number of
approved dairy producers fell from 26,883 to 20,182,
whereas the total volume of milk collected remained rela-
tively steady. In 2008, the Irish dairy industry produced
5.1 million tonnes of milk, equivalent to 0.88% of global
production [2]. However, the industry plays a critical role
to the national economy, accounting for approximately
3% of national gross domestic product [3]. Approxi-
mately 85% of annual production is exported.
The quality of Irish milk and other dairy products is of
paramount importance, both to domestic and interna-
tional consumers. Ireland is the world’s leading producer
of infant nutrition products, producing 15% of the
world’s powdered infant formula [3]. ‘In 2009, the infant
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billion, growing on average at 15% each year [4]. Ireland
is seeking a 50% increase in milk production by 2020,
using 2007-09 as a baseline [5].
A broad range of criteria is used to assess the quality of
raw milk, relating to composition (butterfat, crude pro-
tein, lactose, milk solids etc.) and hygiene (total bacterial
count, somatic cell count, residues of veterinary medi-
cines including antibiotics). Somatic cell count (SCC) is
the most important, single indicator of milk quality,
reflecting the health status of the mammary gland (so-
called ‘udder health’) and the risk of non-physiological
changes to milk composition [6].
There are substantial costs associated with sub-optimal
udder health, both on-farm and during processing, as
reviewed previously [1]. Herds with udder health pro-
blems, generally as a consequence of mastitis (inflamma-
tion of the mammary gland), are also at increasing risk of
antibiotic residue violation, as a result of increased antibio-
tic usage [7,8]. SCC underpins national and international
regulation for milk quality [8], and standards for total
bacterial counts (TBC), SCC and residues of veterinary
medicines are each defined within EU legislation (see
Additional file 1). Uninfected quarters have an average
SCC of approximately 70,000 [9,10] to 100,000 [11] cells/
mL, although this does increase with age. SCC is also
influenced by stage of lactation as a consequence of dilu-
tion, leading to increases in SCC with reduced milk
volume [12,13]. An elevated SCC is indicative of mastitis,
generally caused by presence of infectious microorganisms
[6]. Non-infected and infected quarters are generally dis-
tinguished using a cut-off of 200,000 cells/mL, with a sen-
sitivity and specificity of 74.5% and 89.6%, respectively
[14]. The relationship between infection and SCC is clo-
sest at the level of the quarter, however, SCC is also a
proxy for udder health at the level of the cow, the herd
and the broader population [10]. At the herd level, where
a threshold of 200,000 cells/mL is considered a useful pre-
dictor of intramammary infection [15,16], longitudinal
data (collected over time) is needed to monitor SCC [10].
There have been few publications on udder health and
intramammary antibiotic usage on Irish dairy farms.
Nonetheless, some information from earlier work [17-19]
is available. The current paper seeks to build on this ear-
lier work, presenting insights into udder health and intra-
mammary antibiotic usage in the Irish dairy industry
during 2003-2010, based on data from several sources.
Materials and methods
The data
Three data sources were used in this study, as follows:
Milk recording data
Milk recording is conducted voluntarily in Ireland, with
all data being managed by the Irish Cattle Breeding
Federation (ICBF). We obtained data about all milk
recordings conducted in Ireland during 2003 to 2010,
inclusive. The data included a single herd-level SCC
value for each herd at each milk recording, being the
arithmetic mean of cow-level SCC of each cow at that
recording, weighted by cow-level yield. In addition, at
each milk recording, data were available on the number
of cows sampled and the total volume of milk recorded.
For each herd each year (all years except 2010, where
these data were not available), we also obtained the per-
centage of calves born between 01 January to 30 June
(considered the spring-calving period). In this dataset,
the reference population was all milk recording herds in
Ireland, and the herd-level SCC in each herd at each
milk recording was the primary unit of interest.
Intramammary antibiotic sales data
GfK Kynetec, an international market research company
specialising in agriculture and animal health, gather data
on all intramammary sales conducted through each of
the five main veterinary wholesalers in Ireland. Accord-
ing to GfK Kynetec, this is likely to represent an esti-
mated 85% of all sales of these products in Ireland. We
obtained data from GfK Kynetec, summarised yearly for
each year during 2003 to 2010 inclusive, of sales of intra-
mammary antibiotic products for cows during lactation
and at drying off. In this dataset, the reference population
was all dairy herds in Ireland, and defined quantities of
intramammary antibiotic product (either g of active
ingredient or number of mastitis tubes) were the units of
interest.
Animal health assessment data
In Ireland, each dairy farm is inspected periodically (gener-
ally annually) by a veterinarian to certify compliance with
animal health requirements (the Animal Health Inspection
of Dairy Cows or ‘dairy cert.’). Further information about
the dairy cert. is presented in Additional file 1. We
obtained a yearly summary from the national Department
of Agriculture, Food and the Marine (DAFM) of the num-
ber of herds non-compliant with the dairy cert., during the
y e a r s2 0 0 3t o2 0 0 9( a tt h et i m eo fw r i t i n g ,n od a t aw e r e
available for 2010). In this dataset, the reference popula-
tion was all dairy herds in Ireland, and the non-compliant
dairy farm was the unit of interest.
Data analysis
Milk recording data
Preliminary screening of the milk recording data was
conducted to identify and remove all duplicate (non-
valid) records (arbitrarily, duplicate on-farm milk record-
ings less than 21 days apart). Recordings with more than
50% of samples unreadable, as were milk recording data
with less than 10 cows and/or a SCC less than 20,000
cells/mL. We considered these latter circumstances unre-
presentative of the national herd.
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total and by year), the number of milk-recorded herds
(herds with at least one valid milk recording during a
calendar year; in total and by year) and the number of
milk recordings per herd (by year). Herd size was calcu-
lated, based on the median number of cows per herd
across all milk recordings for that herd. We identified a
subset of herds as ‘strictly spring-calving’ (all herds with
100% of calves born during the spring-calving period). In
2010, herds were allocated based on 2009 data.
We calculated the unadjusted herd SCC (median and
quartile range) per month (the monthly SCC) in all milk-
recorded herds, the percentage of herds each month
where the unadjusted herd SCC exceeded 200,000 and
400,000 cells/mL, and the geometric mean every 6
months, either January to June or July to December. In
each case, if more than one valid milk recording was avail-
able for any month, only the first was used. Data manipu-
lation and analyses were conducted using SAS version
9.1.3 (SAS Institute, Cary, NC, USA). Graphs were created
using Microsoft Excel 2007 (Microsoft Corporation, Red-
mond, WA, USA).
Two logistic generalised estimating-equation (GEE)
models were developed, the outcome variable being either
the probability that the monthly SCC of a herd was greater
than 400,000 cells/mL or less than or equal to 200,000
cells/mL. In each model, an autoregressive correlation was
used to account for the serial correlation between monthly
measurements within the same herd. The terms month,
year, herd size and Spring calving (Spring = 100% of calves
born between January and June, Non-Spring = all other
herds) were included in each model as categorical vari-
ables. Herd size was based on the maximum number of
cows tested within a year and categorised into 4 groups
based on the quartiles of the herd size distribution within
the respective year. Similarly Spring calving was based on
the percentage of calves born between January and June
within each respective year. Terms were assessed for inclu-
sion within each model on the basis of the generalised
score test. Consistent estimates of coefficient standard
errors were obtained using the empirical covariance
matrix of parameter estimates resulting from the GEE
method. The models were fitted using the SAS GENMOD
procedure. Since not all herds were recorded every month,
there will be intermittent missing values for some herds.
The GENMOD procedure estimates the working correla-
tion from data containing missing values using the ‘all
available pairs’ method, in which all non-missing pairs of
data are used in the moment estimators of the working
correlation parameters. Data for 2003 was excluded from
each model as milk recording data from that year were
limited. The fit of the final model was checked using a
half-normal plot of the Pearson residuals with a simulated
envelope [20].
Intramammary antibiotic sales
Each intramammary antibiotic product was categorised
by time of application (in-lactation, dry cow) and the
antibiotic group(s) of the active substance(s), as follows:
￿ Aminocoumarins (novobiocin);
￿ Aminoglycosides (framycetin, kanamycin, neomycin,
streptomycin);
￿ Cephalosporins, either 1st generation (cefacetrile,
cefalexin, cefapirin, cephalonium), 3rd generation (cefo-
perazone), 4th generation (cefquinome);
￿ Lincosamides (lincomycin, pirlimycin);
￿ Macrolides (erythromycin);
￿ Penicillins, either narrow spectrum (b-lactamase sen-
sitive: benzylpenicillin, penethamate; penicillinase-resis-
tance: cloxacillin, nafcillin), moderate spectrum
(ampicillin), broad spectrum (amoxicillin and clavulinic
acid);
￿ Sulphonamides (sulphadiazine, trimethoprim); and
￿ Tetracyclines (oxytetracycline).
Using Microsoft Excel 2007 (Microsoft Corporation,
Redmond, WA, USA), the data were summarised accord-
ing to the number of tubes sold by time of application,
and the quantity of active substance sold by antibiotic
group and time of application. These data were then
used to estimate:
￿ Dry cow therapy (DCT) coverage (the % of lactating
cows receiving dry cow intramammary antibiotic therapy
at drying off), after considering the number of lactating
dairy cows and the total number of DCT tubes sold.
￿ Incidence of clinical mastitis (number of clinical mas-
titis cases per 100 cows per year), after considering the
number of lactating dairy cows, the number of cows at
risk of clinical mastitis, the days at risk per cow, the days
after treatment before a subsequent treatment is consid-
ered a new case, the number of in-lactation tubes sold,
the number of tubes used per treatment regime, the
number of affected quarters per cow and the relative use
of in-lactation tubes for clinical and subclinical mastitis
cases. The incidence rate was calculated based on guide-
lines published by the International Dairy Federation
[21].
Relevant national and EU legislation is presented in
Additional file 1.
Animal health assessment data
A yearly summary was produced, using available data.
Results
Somatic cell counts in milk recording herds
During 2003 to 2010, 297,652 milk recordings were avail-
able, including 295,286 valid milk recordings conducted in
9,057 herds. The number of herds by number of milk
recordings in each herd per year is presented in Table 1
noting that approximately half of the herds made between
4 and 7 recordings each year. The average (median) herd
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Page 3 of 13size was 66.3 (58.0) cows, with a minimum of 10, a maxi-
mum of 765 and an interquartile range of between 44 to
78 cows. Table 2 presents summary statistics for herds
that milk recorded in 2010. Between 41.4% (in 2008) and
46.3% (2010) of milk recording herds were strictly spring-
calving. In 2009, the distribution of herds according to a
spring-calving pattern was: 45.1% of herds with 100%
spring-born calves, 63.5% with > 95% spring-born calves,
70.0% with > 90% spring-born calves, and 94.1% with >
50% spring-born calves.
The distribution of unadjusted herd SCC during 2003
to 2010 is presented in Figure 1. A highly seasonal pat-
tern is evident, with an increase in SCC (both median
and range) between June and December each year. The
percentage and number of herds during this period with
an unadjusted herd SCC exceeding 200,000 and 400,000
cells/mL is presented in Figure 2. The percentage of
herds exceeding 200,000 cells/mL varied from a low of
45% in April 2003 to a high of 86% in December 2009,
and the percentage exceeding 400,000 cells/mL varied
from a low of 9% in May 2007 to a high of 45% in
December 2009. There was also a seasonal pattern in
herd SCC results exceeding 200,000 and 400,000 cells/
mL, except in 2003 (when milk recording data were
sparse) (Figure 2).
The results from the final GEE models are shown in
Tables 3 and 4. For ease of interpretation of the model
the predicted probabilities by Spring calving, year and
month are shown in Figures 3 and 4, in order to calcu-
late the predicted probabilities the other variables were
set to small herds in January (for the year calculations)
and 2004 (for the month calculations).
The odds of a high SCC (> 400,000 cells/mL) was
highest in December, with the lowest probability in May
(Table 3 Figure 3). Spring herds had a lower probability
of a high SCC during February to October compared to
non-Spring herds but a higher probability between
November to January. The odds of a high SCC were
greater in 2005, 2006, 2009 and 2010 but less in 2007
and 2008 compared to 2004. Spring herds had a higher
probability of a high SCC in 2004 and 2005 compared
to non-Spring herds and they had a lower probability in
2010 compared to non-Spring herds (Figure 4). Smaller
herds had higher odds of having a high SCC compared
to larger herds. Pearson residuals were examined using
a half-normal plot with simulated envelope. There were
no indications that the model was inappropriate.
T h eo d d so fal o wS C C( ≤ 200,000 cells/mL) was
highest from February to June, with the lowest probabil-
ity in November (Table 4). Spring herds had a higher
Table 1 Number of herds by number of milk recordings in each herd per year during 2003 to 2010
Number of milk
recordings
2003 (n =
3,296)
2004 (n =
6,287)
2005 (n =
6,033)
2006 (n =
6,228)
2007 (n =
6,230)
2008 (n =
6,400)
2009 (n =
5,776)
2010 (n =
5,924)
Total
1 640 101 128 98 106 130 149 105 1,457
2 815 92 66 94 93 160 141 129 1,590
3 688 150 142 245 246 373 351 333 2,528
4 379 489 738 1,191 1,561 1,880 1,740 1,916 9,894
5 304 670 664 764 753 679 557 682 5,073
6 209 956 823 807 852 866 780 643 5,936
7 128 1033 780 805 725 824 824 978 6,097
8 49 593 492 420 442 289 218 148 2,651
9 22 471 422 334 310 201 156 136 2,052
10 20 544 440 338 288 228 197 198 2,253
11 27 512 469 425 301 268 220 216 2,438
12 15 622 778 657 501 473 416 430 3,892
13 52 83 49 48 29 25 9 295
14 2 8 4 14
15 1 1 2
18 11
22 11
Data on the total number of dairy herds present in Ireland during each of these years were not available
Table 2 Summary statistics for herds that milk recorded during 2010
Parameter Minimum Maximum 25
th percentile Median 75
th percentile
Average milk yield (L) per recording 2.7 49.1 17.7 21.8 25.5
Days in milk per recording 8 627 111 170 217
Number of cows per recording 10 568 42 59 82
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ber, December and January. The odds of a low SCC
were greater in 2004, 2007 and 2008. Spring herds had a
higher probability of a low SCC in 2004, 2009 and 2010.
Smaller herds had higher odds of having a low SCC
compared to larger herds.
Table 5 shows the proportion of herd recordings that
were: ≤ 200,000, > 200,001-400,000, and > 400,000 cells/
mL, by herd size group. Note that the herd size groupings
varied with the respective yearly herd size distribution,
with Q1 being the quarter of smallest herds in the popula-
tion, and Q3 being the quarter of largest herds in the
population. The smallest herds tended to have more
recordings in the extremes of SCC readings (22% were >
400,000, 35% were ≤ 200,000 cells/mL), whilst the largest
herds tended to have a higher proportion of recordings in
the middle SCC range (55% of recordings were > 200,001-
400,000 cells/mL for larger herds).
Figure 1 The distribution (median, percentiles per month; geometric mean every 6 months) of unadjusted herd SCC results, based on
SCC data from milk-recording Irish herds during 2003 to 2010. If more than one valid milk recordings per herd was available for any
month, only the first was used.
Figure 2 The percentage of Irish dairy herds with a SCC result exceeding 200,000 and 400,000 cells/mL based on unadjusted SCC
data from milk-recording herds, and the total number of herds milk recording, during 2003 to 2010. If more than one valid milk
recordings per herd was available for any month, only the first was used.
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Page 5 of 13Table 3 Logistic GEE model for the probability of a herd
with an SCC > 400,000 cells/mL
Variable b S. E. p-value OR 95% CI
Intercept -0.79 0.04 < 0.001 0.45 0.42 0.49
Month 1 0.00 0.00 . 1.00 1.00 1.00
2 -0.15 0.03 < 0.001 0.86 0.82 0.91
3 -0.32 0.03 < 0.001 0.73 0.69 0.76
4 -0.73 0.03 < 0.001 0.48 0.46 0.51
5 -0.83 0.03 < 0.001 0.44 0.41 0.46
6 -0.67 0.03 < 0.001 0.51 0.48 0.54
7 -0.32 0.03 < 0.001 0.73 0.69 0.77
8 -0.39 0.03 < 0.001 0.67 0.64 0.71
9 -0.46 0.03 < 0.001 0.63 0.60 0.67
10 -0.33 0.03 < 0.001 0.72 0.68 0.76
11 0.01 0.03 0.735 1.01 0.96 1.06
12 0.16 0.03 < 0.001 1.17 1.11 1.23
Year 2004 0.00 0.00 . 1.00 1.00 1.00
2005 0.09 0.02 < 0.001 1.09 1.04 1.15
2006 0.08 0.03 0.007 1.08 1.02 1.14
2007 -0.11 0.03 < 0.001 0.90 0.84 0.95
2008 -0.04 0.03 0.167 0.96 0.90 1.02
2009 0.34 0.03 < 0.001 1.40 1.32 1.49
2010 0.38 0.03 < 0.001 1.46 1.37 1.56
Herd size
a Q1 0.00 0.00 . 1.00 1.00 1.00
Q2 -0.15 0.03 < 0.001 0.86 0.81 0.91
Q3 -0.24 0.03 < 0.001 0.79 0.74 0.84
Q4 -0.31 0.04 < 0.001 0.73 0.68 0.79
Spring Calving Non-Spring 0.00 0.00 . 1.00 1.00 1.00
Spring 0.15 0.07 0.049 1.16 1.00 1.34
Spring × Month
b Spring: 1 1 0.00 . 1.00 1.00 1.00
Spring: 2 1 -0.27 < 0.001 0.76 0.66 0.88
Spring: 3 1 -0.43 < 0.001 0.65 0.56 0.75
Spring: 4 1 -0.44 < 0.001 0.64 0.56 0.74
Spring: 5 1 -0.48 < 0.001 0.62 0.53 0.71
Spring: 6 1 -0.60 < 0.001 0.55 0.48 0.63
Spring: 7 1 -0.65 < 0.001 0.52 0.45 0.60
Spring: 8 1 -0.61 < 0.001 0.54 0.47 0.62
Spring: 9 1 -0.50 < 0.001 0.61 0.53 0.70
Spring: 10 1 -0.28 < 0.001 0.76 0.66 0.87
Spring: 11 1 0.05 0.478 1.05 0.91 1.21
Spring: 12 1 0.36 < 0.001 1.43 1.23 1.68
Spring × Year
b Spring: 2004 0.00 0.00 . 1.00 1.00 1.00
Spring: 2005 -0.05 0.05 0.310 0.95 0.86 1.05
Spring: 2006 -0.11 0.05 0.037 0.90 0.81 0.99
Spring: 2007 -0.16 0.06 0.004 0.85 0.76 0.95
Spring: 2008 -0.14 0.06 0.015 0.87 0.78 0.97
Spring: 2009 -0.14 0.06 0.010 0.87 0.78 0.97
Spring: 2010 -0.31 0.06 < 0.001 0.73 0.66 0.82
a Herd size groups were based on the quartile of the herd size within each
year
b Non-Spring herds were the reference category and set to 0
Table 4 Logistic GEE model for the probability of a herd
with an SCC ≤ 200,000 cells/mL
Variable b S. E. p-value OR 95% CI
Intercept -0.72 0.04 < 0.001 0.49 0.45 0.52
Month 1 0.00 0.00 . 1.00 1.00 1.00
2 0.17 0.03 < 0.001 1.18 1.12 1.24
3 0.28 0.03 < 0.001 1.32 1.26 1.39
4 0.48 0.03 < 0.001 1.62 1.54 1.71
5 0.53 0.03 < 0.001 1.70 1.62 1.79
6 0.33 0.03 < 0.001 1.39 1.32 1.47
7 0.00 0.03 0.908 1.00 0.95 1.06
8 -0.04 0.03 0.133 0.96 0.91 1.01
9 -0.12 0.03 < 0.001 0.89 0.84 0.94
10 -0.29 0.03 < 0.001 0.75 0.71 0.79
11 -0.40 0.03 < 0.001 0.67 0.64 0.71
12 -0.29 0.03 < 0.001 0.75 0.71 0.80
Year 2004 0.00 0.00 . 1.00 1.00 1.00
2005 -0.15 0.02 < 0.001 0.86 0.82 0.90
2006 -0.19 0.03 < 0.001 0.82 0.78 0.87
2007 -0.06 0.03 0.036 0.94 0.89 1.00
2008 0.03 0.03 0.284 1.03 0.97 1.09
2009 -0.26 0.03 < 0.001 0.77 0.73 0.82
2010 -0.48 0.03 < 0.001 0.62 0.58 0.66
Herd size
a Q1 0.00 0.00 . 1.00 1.00 1.00
Q2 -0.10 0.03 0.001 0.91 0.86 0.96
Q3 -0.15 0.03 < 0.001 0.86 0.81 0.91
Q4 -0.36 0.03 < 0.001 0.70 0.65 0.75
Spring calving Non-Spring 0.00 0.00 . 1.00 1.00 1.00
Spring -0.10 0.08 0.211 0.91 0.78 1.06
Spring × Month
b Spring: 1 0.00 0.00 . 1.00 1.00 1.00
Spring: 2 0.47 0.07 < 0.001 1.61 1.39 1.86
Spring: 3 0.40 0.07 < 0.001 1.49 1.30 1.72
Spring: 4 0.38 0.07 < 0.001 1.46 1.27 1.68
Spring: 5 0.38 0.07 < 0.001 1.46 1.27 1.68
Spring: 6 0.42 0.07 < 0.001 1.53 1.33 1.76
Spring: 7 0.49 0.07 < 0.001 1.63 1.41 1.88
Spring: 8 0.46 0.07 < 0.001 1.58 1.37 1.83
Spring: 9 0.36 0.07 < 0.001 1.44 1.24 1.66
Spring: 10 0.14 0.07 0.056 1.15 1.00 1.33
Spring: 11 -0.27 0.08 0.001 0.76 0.66 0.89
Spring: 12 -0.37 0.09 < 0.001 0.69 0.58 0.83
Spring × Year
b Spring: 2004 0.00 0.00 . 1.00 1.00 1.00
Spring: 2005 0.05 0.04 0.221 1.05 0.97 1.15
Spring: 2006 0.07 0.05 0.107 1.08 0.98 1.18
Spring: 2007 0.11 0.05 0.017 1.12 1.02 1.23
Spring: 2008 0.08 0.05 0.076 1.09 0.99 1.20
Spring: 2009 0.17 0.05 0.001 1.19 1.08 1.31
Spring: 2010 0.31 0.05 < 0.001 1.36 1.23 1.51
a Herd size groups were based on the quartile of the herd size within each
year
b Non-Spring herds were the reference category and set to 0
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The number of intramammary tubes sold annually in
Ireland during 2003-2010, by product type (in-lactation
and dry cow use) is presented in Figure 5. Table 6 pre-
sents the quantity of active substance (kg) in intramam-
mary tubes sold annually in Ireland during 2003-2010,
by product type (in-lactation and dry cow use) and anti-
biotic group. Almost 2 tonnes of active substance (1,677
kg of active substance for in-lactation and dry cow use,
data represents 85% of sales) was sold for use in 2010,
from a range of antibiotic groups (for in-lactation usage:
aminoglycocides, broad spectrum penicillins and 1
st gen-
eration cephalosporins [from most frequent by weight];
for DCT: penicillinase-resistant narrow spectrum peni-
cillins, 1
st generation cephalosporins and b-lactamase
sensitive, narrow spectrum penicillins for DCT).
Figure 3 The predicted probability of a herd either having a SCC result exceeding 400,000 cells/mL or < = 200,000 cells/mL based on
the results from the final logistic GEE models for small herds (Q1) in 2004 comparing herds calving in Spring against all other herds.
Figure 4 The predicted probability of a herd either having a SCC result exceeding 400,000 cells/mL or < = 200,000 cells/mL based on
the results from the final logistic GEE models for small herds (Q1) in January comparing herds calving in Spring against all other
herds.
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mately 92.7% (Table 7). The estimated incidence of clin-
ical mastitis was 54.0 cases per 100 cow-years at risk,
assuming 4 tubes per treatment regime, one affected
quarter per cow, tubes restricted to clinical cases only
and 100% of treated cases considered new cases (Table
8). With differing assumptions, this estimate varied
between 25.8 and 77.0 cases per 100 cow-years at risk.
Animal health assessment
During 2003 to 2009, there were no known cases where
a dairy cert. had not been issued.
Discussion
Objective measurement is critical to improvement. For
t h i sr e a s o n ,i ti si m p o r t a n tt h a tI r e l a n dh a sa no b j e c t i v e
understanding of current levels of udder health, to
facilitate benchmarking and improvement into the
future. This is particularly important, given the recent
establishment of CellCheck, a national programme to
support SCC improvement throughout Ireland, as dis-
cussed later.
Udder health is a concern on a number of Irish dairy
farms. As highlighted in Figures 1 and 2, a substantial
number of milk-recorded herds had an elevated unad-
justed herd SCC (exceeding 400,000 cells/mL) during
the study period (2003 to 2010). High SCC results were
present throughout the year, but more marked towards
the start and end of each milking season. Note that milk
supply in Ireland is highly seasonal, as reflected in Fig-
ure 2 (specifically, the number of herds that milk
recorded during the years of interest). Compared with
2004, the odds of a herd having an SCC > 400,000 cells/
mL were greater in 2005, 2006, 2009 and 2010, but less
in 2007 and 2008. Further, herds in 2009 and 2010 had
a 30% higher odds of having an SCC > 400,000 cells/mL
compared to herds in 2004. Smaller herds tended to
have more extreme SCC recordings (very low and very
high) compared with larger herds. These results confirm
earlier concerns from previous Irish studies [17], where
an analysis of bulk milk tank (payment) data during
1994 to 2004, inclusive, was conducted. In this study
[17], a year-on-year increase in SCC from 2000 was
noted. Bulk milk tank data provides insight into the
quality of milk at the point of dispatch from a farm,
noting that farmers may withhold cows with high SCC
from the bulk tank. In contrast, milk recording is gener-
ally conducted on all cows lactating at the time of
recording, providing a more accurate reflection of on-
farm udder health. Based on the results of an earlier
Irish study, milk recording herds have lower cell counts
than the national average [18].
In this paper, we have used intramammary antibiotic
sales data to estimate both DCT coverage and the inci-
dence of clinical mastitis in Ireland during 2010.
Although no alternative data are currently available,
these estimates must be interpreted with caution. Each
is underpinned by both estimates (of lactating cow num-
bers, of total sales) and assumptions. For this reason, we
have conducted a sensitivity analysis with each calcula-
tion, highlighting the impact of changes in these
assumptions on DCT coverage and clinical mastitis inci-
dence. We estimate that the GfK Kynetec sales data
represents approximately 85% of total sales, guided by
those closely involved in this industry. Manufacturers
generally recommend 3 tubes per treatment regime,
however, Blowey and Edmondson [22] suggest the aver-
age usage in the UK is closer to 4-5 tubes per cow. In
Ireland, some farmers may use fewer tubes per treat-
ment regime, to minimise treatment costs. In our calcu-
lations, we consider a range in the number of tubes per
Table 5 Proportion of herd recordings within each
grouping of SCC, by herd size group
SCC
Herd size < = 200 201-400 > 400
Q1 35.52 42.35 22.12
Q2 33.06 46.99 19.96
Q3 31.38 49.47 19.15
Q4 26.50 54.74 18.76
Figure 5 The number of intramammary antibiotic tubes sold
annually in Ireland during 2003-2010, by product type (in-
lactation and dry cow use).
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Page 8 of 13treatment regime. No account was taken of repeat cases
as such data were not available, which will lead to some
inflation of estimates of clinical case incidence. In pro-
spective studies, repeat cases (defined as one that recurs
in the same quarter more than one week after the last
day of treatment [23]) can be avoided by discarding any
cows with a case of clinical mastitis in the previous four
weeks [24].
Based on the data presented (Table 8), blanket DCT is
common practice throughout Ireland, with estimated
coverage of 92.7%. Blanket DCT is generally recom-
mended as part of a comprehensive on-farm mastitis
control plan, except on farms where mastitis is under
very good control (comprehensive individual milk
recording, clear microbiological picture, few cows with
peak SCC over 250,000 cells/ml etc.), with a low preva-
lence of infected cows at drying off, and a low rate of
new intra-mammary infections in the dry period.
The study results reflect a relatively high incidence of
clinical mastitis in Ireland (54.0 clinical cases per 100
cow-years at risk) using methods recommended by the
International Dairy Federation [21]. This estimate is very
dependent on the assumptions used, as outlined in Table
8. Further, we assume that tubes were restricted to clini-
cal cases. The incidence of clinical mastitis in dairy cattle
varies widely, due to differences in a range of factors
including climate, level of production and management
[24]. In the UK, a mean incidence rate of clinical mastitis
of between 47 and 71 cases per 100 cows per year was
identified [24], which is higher than reported previously
[25]. In the Netherlands, Miltenburg et al. [26] calculated
an incidence rate of 12.7 quarter cases per 100 cows per
year (repeat cases considered new if > 14 days apart). In
Australia, professional input is recommended within the
Countdown Downunder programme when clinical cases
exceeds 5 per 100 cows during the first month of
Table 6 The quantity of active substance (kg) in intramammary tubes sold annually in Ireland during 2003-2010, by
product type (in-lactation [Lact.] and dry cow [DC] use) and antibiotic group
2003 2004 2005 2006 2007 2008 2009 2010
Lact. DC Lact. DC Lact. DC Lact. DC Lact. DC Lact. DC Lact. DC Lact. DC
Aminocoumarin 56.6 0.2 50.5 - 45.6 - 40.8 - 48.8 - 42.9 - 41.4 - 51.9 1.6
Aminoglycosides 269.6 53.8 239.8 43.8 227.6 38.6 206.7 33.7 230.2 32.8 259.9 90.1 218.0 66.5 170.0 38.8
Cephalosporins
1
st generation 85.6 147.5 80.3 156.4 74.2 165.1 71.2 171.5 68.5 212.6 77.6 270.6 74.3 274.0 89.1 296.5
3
rd generation 2.0 - 2.1 - 3.6 - 3.7 - 4.0 - 4.5 - 4.3 1.1 8.3 8.1
4
th generation 1.0 - 1.3 - 1.8 - 1.4 - 2.2 - 2.5 - 1.8 - 2.0 -
Lincosamides 10.5 - 5.4 - 4.6 - 3.6 - 3.4 - 4.7 - 3.4 - 3.9 -
Macrolides 0 . 9 - 0 . 6 - 0 . 2 -- - --------
Pencillins
Narrow spectrum
b-lactamase
sensitive
120.3 204.3 104.9 163.3 100.3 145.1 89.7 114.8 101.7 128.0 107.3 137.5 91.2 137.2 55.5 167.6
Penicillinase-
resistant
3.1 656.4 2.7 532.6 3.1 512.6 3.8 448.0 2.3 686.7 1.7 635.3 1.6 528.4 2.9 511.5
Moderate spectrum 1.1 161.8 1.0 147.2 1.2 144.8 1.4 133.0 0.9 204.9 0.6 144.7 0.6 114.0 1.1 139.2
Broad spectrum 97.7 - 87.7 - 89.4 - 92.2 - 105.5 - 102.0 - 101.2 - 124.7 -
Sulphonamides 1.7 - 1.5 - 1.2 - 0.6 - 17.1 - 5.0 - 3.1 - 3.7 -
Tetracyclines 3.6 - 3.6 - 4.2 - 3.9 - 4.6 - 11.9 - 4.4 - - -
Total 653.6 1,224.0 581.5 1,043.2 556.8 1,006.3 519.1 900.9 589.2 1,265.0 620.6 1,278.2 545.4 1,121.2 513.3 1,163.3
Table 7 Estimated coverage of dry cow therapy (DCT) in Ireland during 2010, based on DCT sales collated by GfK
Kynetec
Explanation, assumptions
i. Approximate number of dairy cows
(2010)
1,000,000 Includes all milking cows (lactation 1+)
ii. Approximate number eligible for DCT 800,000 i. minus (cows in final lactation), assume 5 lactations. DCT is not administered to yet-to-calve
heifers
iii. Number of dry cow tubes sold (2010) 2,522,500 As collated by GfK Kynetec
iv. Total number of dry cow tubes sold 2,967,647 Assuming iii. represents 85% of all DCT sales
v. Estimated DCT coverage 92.7%
a Assuming a single tube per quarter, four quarters per cow
a. This figure would be 98.5% or 87.6% if GfK Kynetec data represents 80% or 90% of national DCT sales, respectively
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Page 9 of 13lactation or 2 per 100 cows in each month subsequently
(a maximum of 23 cases per 100 cows per year, assuming
a 10 month lactation) [27].
There is widespread concern about the use of unneces-
sary and excessive use of antibiotics in farm animals [28],
with significant implications for human health, particu-
larly in terms of antibiotic resistance [29]. There is parti-
cular concern with the non-therapeutic use of antibiotics,
primarily in the form of feed additives, particularly during
poultry and pig production [29]. The impact of antibiotic
use in dairy cows was recently reviewed [30]. Based on
this review, there is currently no evidence of ‘widespread,
emerging resistance among mastitis pathogens to anti-
bacterial drugs’. However, ‘the use of antibiotics in food-
producing animals does contribute to increased antimi-
crobial resistance’, highlighting the need for ‘prudent use
of antibiotics in the dairy industry’.
In this paper, we infer characteristics of on-farm intra-
mammary antibiotic usage based on sales data collated
by GfK Kynetec. In most countries, including Ireland,
data on antibiotic usage is generally not available [31].
Several published reports of on-farm intramammary
antibiotic usage are available, for example from Switzer-
land [32] and the USA [33,34], however, these have
relied on farm surveys. In a recent review [31], it was
recommended that national monitoring programmes be
established of antimicrobial usage in food animals, using
data from a range of sources including sales data, with
these data being reported annually, including the total
amounts of each compound and kilograms of each
active ingredient. Similar suggestions were made in a
recent communication from the European Commission
on antimicrobial resistance, with key recommendations
including:
Table 8 Estimated incidence of clinical mastitis (cases per 100 cows per lactation) in Ireland during 2010, using three
different scenarios (with differing numbers of tubes per treatment regime) and based on DCT sales collated by GfK
Kynetec
Explanation, assumptions
i. Approximate number of dairy cows (2010) 1,000,000 Includes all milking cows, assuming an average 5 lactations/cow
ii. Number of cows at risk of clinical mastitis 1,000,000 Equals i. (all lactating cows are at risk of clinical mastitis)
iii. Days at risk per cow 335 Assumes 305 day lactation, 60 day dry period and cows are at risk from
30 days prior to calving until drying off
a
iv. Days after treatment before a subsequent treatment is
considered a new case
8 As recommended
a
v. Number of in-lactation tubes sold (2010) 1,664,066 As collated by GfK Kynetec
vi. Total number of in-lactation tubes sold 1,957,725 Assuming v. represents 85% of all DCT sales
Scenario 1: 3 tubes per treatment regime
1.i Total number of treated clinical cases 652,575 Assuming 3 tubes per treatment regime, one affected quarter per cow,
tubes restricted to clinical cases only
1.
ii
Total number of new cases 652,575 100% of treated cases considered new cases
1.
iii
Number of clinical cases per 100 cow-years at risk 72.4
b, c
Scenario 2: 4 tubes per treatment regime
2.i Total number of treated clinical cases 489,431 Assuming 4 tubes per treatment regime, one affected quarter per cow,
tubes restricted to clinical cases only
2.
ii
Total number of new cases 489,431 100% of treated cases considered new cases
2.
iii
Number of clinical cases per 100 cow-years at risk 54.0
b, c
Scenario 3: 5 tubes per treatment regime
3.i Total number of treated clinical cases 391,545 Assuming 5 tubes per treatment regime, one affected quarter per cow,
tubes restricted to clinical cases only
3.
ii
Total number of new cases 391,545 100% of treated cases considered new cases
3.
iii
Number of clinical cases per 100 cow-years at risk 43.1
b, c
a. Based on recommendations of the International Dairy Federation [21]
b. Without changing any other assumptions, if GfK Kynetec data represents 80% or 90% of national DCT sales, the incidence of clinical cases would range from
77.0 to 68.3 in scenario 1, 57.5 to 51.0 in scenario 2 and 45.8 to 40.7 in scenario 3, respectively
c. Without changing any other assumptions, if the percentage of treated cases considered new cases were 80% or 60%, the incidence of clinical cases per 100
cow-years at risk would be 57.7 or 43.1 for scenario 1, 43.1 or 32.3 for scenario 2 and 34.4 or 25.8 for scenario 3, respectively
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Page 10 of 13￿ Strengthening the regulatory framework on veter-
inary medicines, seeking prudent use of antimicro-
bials in veterinary medicine (action no. 2);
￿ Introducing the new EU Animal Health Law,
which will focus on prevention of diseases, reducing
the use of antibiotics and replacing current Animal
Health provisions based on disease control (action
no. 5); and
￿ Strengthening surveillance systems on antimicro-
bial resistance and antimicrobial consumption in
animal medicine, including promotion and extension
of the European Surveillance of Veterinary Antimi-
crobial Consumption (ESVAC). to obtain harmo-
nized data on the usage per animal species and
production categories (action no. 10) [35].
The use of intramammary antibiotics in the Irish dairy
industry is regulated under both Irish and EU law. The
GfK Kynetec sales data provides a valuable insight into
on-farm usage. Nonetheless, we acknowledge that our
usage estimates must be interpreted with care. During
2003-2010, there appears to have been substantial usage
of intramammary antibiotics in the Irish dairy herd.
Unfortunately, few international comparisons are avail-
able. Some interpretation of this usage is possible, incor-
porating this and other data. As background, it is
important to be aware that Staphylococcus aureus is the
most frequently isolated mastitis pathogen in Ireland,
based on culture results from milk sample submissions
to Regional Veterinary Laboratories during 2005-2010
[36-39] and a study of 300 bulk milk tank samples col-
lected during 2006 [19]. In 2009, S. aureus was isolated
from 43.6% of 5,004 milk sample submissions [39].
Given this microbiological picture, the common practice
of blanket DCT in Ireland (as highlighted previously) is
consistent with rational antibiotic usage. In contrast,
t h e s ed a t as u g g e s tah i g hr a t eo fa n t i b i o t i cu s a g ed u r i n g
lactation, most likely in response to clinical cases of
mastitis. However, the efficacy of mastitis therapy for
chronic Staphylococcus aureus infection during lactation
is extremely low, leading to very low cure rates follow-
ing treatment [30]. Therefore, there may be an over-reli-
ance on antibiotics in the dairy industry in Ireland in
situations where the efficacy of treatment is low. Based
on the data available, we do not observe any substantive
impact of legislative change (in January 2008) on intra-
mammary antibiotic sales in Ireland. More work is
needed nationally to both evaluate and monitor intra-
mammary antibiotic usage, including comparison with
international models of best practice.
The dairy cert. (or Animal Health Inspection of Dairy
Cows) was introduced by the Irish government as a
means to certify compliance with animal health require-
ments. It is of surprise that all herds have been found in
compliance in each of the years under study, particularly
given the scope of the above-mentioned udder health
concerns. It should be noted that the wording of the
dairy cert. is ambiguous or otherwise open to interpreta-
tion, which may limit its usefulness. As one example,
veterinarians are asked to certify that farms are compli-
ant with the requirement of ’... a general state of health
that is not impaired by.. a recognisable inflammation of
the udder.’ This could be interpreted to include any
herd with mastitic cows at the time of inspection, a
requirement that would be difficult to achieve in any
large dairy farm internationally. A critical assessment of
the usefulness of the dairy cert. would seem justified.
In this study, we used three different data sources to
gain an insight into udder health on Irish dairy farms.
This approach was needed, as no national data are avail-
able providing a complete picture of udder health in Ire-
land. Each of these data sources has its strengths and
limitations. The milk recording data are robust, provid-
ing an accurate picture of udder health among the cows
under test. By definition, however, it only relates to milk
recording herds; in 2008, milk recording was conducted
on 32% (6,400 of an estimated 20,000) of Ireland’sd a i r y
herds. Further, milk recording only became widely
established in 2004, hence the scarcity of data prior to
this. The GfK Kynetec dataset was based on actual sales,
with account being taken of any product returns. These
(sales) data are comprehensive, including most, but not
all, sales of these products in Ireland. In this study, we
have used these sales data to estimate on-farm usage,
providing a detailed outline of all relevant assumptions
in Tables 7 and 8. The animal health assessment data is
collated at the level of the cooperative, with any aberra-
tions reported centrally to DAFM.
Animal Health Ireland (AHI) is Ireland’sn a t i o n a l
coordinating body in non-regulatory animal health
[40,41]. AHI recently established CellCheck as the
national programme to support SCC improvement
throughout Ireland. The programme is supported by all
sectors in the dairy industry (including farmers, coop-
eratives, processors and national coordinating groups),
by government and by all relevant service providers
(veterinarians, Teagasc [the Irish Agriculture and Food
Development Authority] and other milk quality advisors,
milking machine technicians), noting that industry stan-
dards and economic signals will play a key role in moti-
vating continuous improvement. The CellCheck
programme is multifaceted, but includes the develop-
ment of detailed resource material suitable for farmers
and their service-providers, and associated training pro-
grammes. AHI is working closely with ICBF to develop
farm-based and national tools to monitor and analyse
progress, and with universities and Teagasc to conduct
relevant economic and sociological research. The
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Page 11 of 13programme is an adaptation of Countdown Downunder
[27,42], a highly successful programme to resolve SCC
concerns in Australia.
The current work provides insights into udder health
and intramammary antibiotic usage in Ireland during
the last 8 years. This information is critical, providing
an objective benchmark for improvement. Similar work
is needed into the future. We are also contributing to
additional research in support of CellCheck.I nc o l l a -
boration with relevant stakeholders, from industry, gov-
ernment and service providers, we are investigating
challenges (political, economic, social and technological)
and opportunities to improving udder health in Ireland.
Work is also ongoing to investigate the effect of data
adjustment, as outlined in EU legislation, on herd elig-
ibility to supply raw milk for human consumption.
Additional material
Additional file 1: An objective assessment of milk quality in Ireland
during 2003-2010 [43-59].
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